menu
Intellia Therapeutics Head office building

Press Releases

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

CAMBRIDGE, Mass. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced the pricing of an underwritten public offering of 6,250,000
Read More

Intellia Therapeutics Announces Proposed Public Offering of Common Stock

CAMBRIDGE, Mass. , Nov. 01, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (Nasdaq:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, today announced that it has commenced an underwritten public offering of
Read More

Intellia Therapeutics Announces Third Quarter 2017 Financial Results

First company to demonstrate dose-dependent CRISPR/Cas9 liver editing in non-human primates, including editing of over 20 percent in certain animals, following systemic delivery of Intellia’s proprietary, non-viral, lipid nanoparticle delivery system Well-tolerated safety profile observed to date
Read More

Intellia Therapeutics to Hold Conference Call to Discuss Third Quarter 2017 Earnings

CAMBRIDGE, Mass. , Oct. 30, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of curative therapeutics using CRISPR/Cas9 technology, will present third quarter 2017 results to investors and analysts in a conference call
Read More

Intellia Therapeutics to Present at October Healthcare Investor Conferences

CAMBRIDGE, Mass. , Oct. 03, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at the following upcoming healthcare conferences in October:
Read More

Intellia Therapeutics Demonstrates Sustained and Durable Genome Editing with CRISPR/Cas9 in One-Year Animal Study

First-in-class, one-year data demonstrate sustained TTR protein reduction of approximately 97 percent, corresponding to 70 percent liver editing, following a single in vivo systemic dose in mice Non-human primate studies ongoing and leading to development candidate designation in first half 2018
Read More

Intellia Therapeutics to Present at Upcoming September Investor Healthcare Conferences

CAMBRIDGE, Mass. , Sept. 07, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR/Cas9 technology, will present at key September investor healthcare conferences.
Read More

 Intellia Therapeutics Announces Second Quarter 2017 Financial Results

In non-human primates, demonstrated robust green fluorescent protein expression throughout the liver 24 hours following a single, systemically delivered, intravenous dose, using our proprietary lipid nanoparticle delivery system Using our proprietary lipid nanoparticle delivery system, demonstrated
Read More

CRISPR Therapeutics, Intellia Therapeutics, Caribou Biosciences and ERS Genomics Announce Appellate Brief Seeking Reversal of U.S. Patent Board Decision on CRISPR/Cas9 Gene Editing

Appeal seeks reversal of Patent Trial and Appeal Board decision terminating interference without determining priority of inventorship of CRISPR/Cas9 gene editing Brief asserts that the Board failed to properly apply controlling U.S. Supreme Court and Federal Circuit precedents, and ignored evidence
Read More

Intellia Therapeutics Names Moncef Slaoui, Ph.D. and Frank Verwiel, M.D. to Its Board of Directors and Establishes a Science and Technology Committee

CAMBRIDGE, Mass. , July 24, 2017 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on the development of potentially curative therapeutics using CRISPR technology, announced today the appointment of Moncef Slaoui , Ph.D. and Frank Verwiel , M.D.
Read More
RSS FEEDS
PRINT PAGE